MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Annals of Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,693 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,693 works in the cohort · of 4,299,418page 45 of 54

Labels cover 15 of 2,693 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,693 of 2,693 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
LBA91 Patient (pt) reported outcomes (PROs) from AMPLITUDE, a randomized placebo-controlled phase III trial of niraparib (NIRA) and abiraterone acetate (AA) plus prednisone (P) in metastatic hormone-sensitive prostate cancer (mHSPC) with homologous recombination repair mutations (HRRm)
D.E. Rathkopf, N. Agarwal, Julie N. Graff, Simran Sandhu, E. Efstathiou, Mustafa Özgüroğlu +14 more
2025· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
fundno affno abstractunlabeled
641TiP Phase Ib/II trial of pembrolizumab (pembro) + vibostolimab combination therapy in patients (Pts) with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE): KEYNOTE-365 cohorts G and H
Johann S. de Bono, Neal D. Shore, Gero Kramer, Anthony M. Joshua, X.T. Li, Christian Poehlein +2 more
2021· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
694TiP DASL-HiCaP: Darolutamide augments standard therapy for localised very high-risk cancer of the prostate (ANZUP1801). A randomised phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation
Tamim Niazi, Scott Williams, Ian D. Davis, Martin R. Stockler, Andrew Martin, Karen Bracken +13 more
2020· article· en· Annals of Oncology· Medicine
machine prediction:candidate · noneconsensus · none
0
citations

How this was built: Screen · Findings · About